Loading organizations...
Helico Bio was a biotechnology company, co-founded in 2020 in Auckland, New Zealand, by Ilya Vensky (CEO) and Xiaoming Wang, alongside other plant and computational scientists. Its core mission involved designing plants to manufacture life-saving medicines, employing advanced computational biology and synthetic biology approaches to engineer novel biological systems. The company aimed to leverage plant biology as a highly efficient and innovative production platform for various complex medicinal compounds, specifically targeting the biopharmaceuticals sector. Operating on venture funding, primarily secured through SAFE (Simple Agreement for Future Equity) instruments, Helico Bio pursued groundbreaking plant-based medicine manufacturing. However, despite its pioneering efforts and innovative approach, the company ultimately failed to achieve its strategic goals. The board subsequently entered Helico Bio into liquidation, reportedly owing millions to its SAFE investors.
Helico has raised $1.3M across 1 funding round.
Helico has raised $1.3M in total across 1 funding round.
Helico has raised $1.3M across 1 funding round. Most recently, it raised $1.3M Seed in May 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 17, 2022 | $1.3M Seed | Icehouse Ventures | David Ross, Wolfgang Leitner | Announced |
Helico has raised $1.3M in total across 1 funding round.
Helico's investors include Icehouse Ventures, David Ross, wolfgang leitner.
